Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)

• Status: Recruiting
• Trial end date: 2023-07-01

Summary

The purpose of this study is to test the safety of combined use of the study drugs, copanlisib and ibrutinib, in people with PCNSL.

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: Memorial Sloan Kettering Cancer Center